Urinary Proteomic Assessment of Ovarian Malignancy and Disease Progression

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The goal of this observational study is to determine the urinary proteomic characteristics in women with and without ovarian cancer. The main questions it aims to answer are: 1. What is the difference in urinary protein composition between patients with ovarian cancer and those without it? 2. Can these differences in urinary protein composition aid in the diagnosis of ovarian cancer? 3. Are urinary protein markers associated with tumor burden in urine samples from patients with ovarian cancer? 4. Can urinary protein markers be used for disease surveillance in ovarian cancer patients?

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Female patients in the gynecological ward for surgical treatment.

• Initial diagnosis of pelvic mass or malignant ascites may be considered as ovarian cancer; Or the initial diagnosis of ovarian cyst, hydrosalpinx, uterine fibroids or uterine adenomyosis are considered as gynecological non-malignant diseases.

• Over 18 years of age.

• Voluntary participation and signing of informed consent.

Locations
Other Locations
China
Xiangya Hosipital of Central South University
RECRUITING
Changsha
Contact Information
Primary
Yu Zhang, PhD
xyzhangyu@csu.edu.cn
+86 0731-89753999
Time Frame
Start Date: 2025-01-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 240
Treatments
Diagnosis undetermined
Patients who are initially diagnosed with conditions such as pelvic mass or malignant ascites, which may suggest ovarian cancer, or those who are initially diagnosed with conditions such as ovarian cyst, hydrosalpinx, uterine fibroids, or adenomyosis, which are considered non-malignant gynecological diseases, and who have not yet undergone any surgery or treatment.
Related Therapeutic Areas
Sponsors
Leads: Xiangya Hospital of Central South University

This content was sourced from clinicaltrials.gov